At a glance
ClinicalIndex Comparison Record- ✓Age 18 to 60 years
- ✓Primary diagnosis of Obsessive-Compulsive Disorder
- ✓Physically healthy and not pregnant
- ✓Off all psychotropic medications except SSRIs, and off other drugs likely to interact with nabilone
- ✕Pregnant or nursing females
- ✕History of significant medical condition increasing risk of participation
- ✕Lifetime psychiatric disorder other than OCD (e.g., psychosis or bipolar disorder)
- ✕Current substance use disorder or positive urine toxicology at screening
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cannabinoid Medication for Adults With Obsessive-Compulsive Disorder (OCD)
In Brief
A Phase 2 clinical trial evaluating Nabilone and Exposure and Response Prevention Therapy for Obsessive-Compulsive Disorder. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this pilot research study is to test the effects of a medication called nabilone (Cesamet) in adults with obsessive-compulsive disorder (OCD). Participants will receive either nabilone on its own, or nabilone in combination with a form of cognitive-behavioral therapy (CBT) called exposure and response prevention (EX/RP). Nabilone is a synthetic cannabinoid and acts on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD.
Study Details
Timeline
Interventions
Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD.
Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.